Bioventus Q1 net loss $14.8M vs prior-year income; reaffirms FY22 guidance

Bioventus Inc.

2022-Q1 EPS reported -$0.19 revenue$117,290,000

Net sales $117.3M (+43.4% YoY as reported, +8.6% organic); Pain Treatments +25.3%, Restorative Therapies +57.5%, Surgical Solutions +67.6%.
Net loss of ($14.8M) compared to net income of $24.5M in Q1 2021; Adjusted EBITDA $7.1M vs $11.1M.
Reaffirms FY2022 guidance: net sales $545M-$565M, Adjusted EBITDA $94M-$107M.
Cash $27.4M; debt $368.3M as of April 2, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.